Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Pfizer-BioNTech COVID-19 Booster Update

Last updated on

On January 3, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include:

  • Authorization of a booster dose for people 12 and older.
  • A shortened interval of 5 months between a booster dose and completion of the primary vaccine series for people 12 and older.
  • A third primary series dose allowed for certain immunocompromised children 5 to 11 years old.

The Texas Health and Human Services Commission (HHSC) allows pharmacy benefit coverage of the Pfizer-BioNTech COVID-19 vaccine in compliance with the expanded use authorized by the FDA.

Email with questions or comments.